TY - JOUR AU - Pradier, Laurent AU - Blanchard-Brégeon, Véronique AU - Bohme, Andrees AU - Debeir, Thomas AU - Menager, Jean AU - Benoit, Patrick AU - Barneoud, Pascal AU - Taupin, Véronique AU - Bertrand, Philippe AU - Dugay, Philippe AU - Cameron, Béatrice AU - Shi, Yi AU - Naimi, Souad AU - Duchesne, Marc AU - Gagnaire, Marie AU - Weeden, Tim AU - Travaline, Tara AU - Reczek, David AU - Khiroug, Leonard AU - Slaoui, Mohamed AU - Brunel, Pascale AU - Fukuyama, Hidehiro AU - Ravetch, Jeffrey AU - Canton, Thierry AU - Cohen, Caroline PY - 2018 DA - 2018/11/28 TI - SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA) JO - Alzheimer's Research & Therapy SP - 117 VL - 10 IS - 1 AB - Anti-amyloid β (Aβ) immunotherapy represents a major area of drug development for Alzheimer’s disease (AD). However, Aβ peptide adopts multiple conformations and the pathological forms to be specifically targeted have not been identified. Aβ immunotherapy-related vasogenic edema has also been severely dose limiting for antibodies with effector functions binding vascular amyloid such as bapineuzumab. These two factors might have contributed to the limited efficacy demonstrated so far in clinical studies. SN - 1758-9193 UR - https://doi.org/10.1186/s13195-018-0447-y DO - 10.1186/s13195-018-0447-y ID - Pradier2018 ER -